75 related articles for article (PubMed ID: 25276866)
1. Rituximab-Au nanoprobes for simultaneous dark-field imaging and DAB staining of CD20 over-expressed on Raji cells.
Fan L; Lou D; Zhang Y; Gu N
Analyst; 2014 Nov; 139(22):5660-3. PubMed ID: 25276866
[TBL] [Abstract][Full Text] [Related]
2. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression.
Song L; Zhang W; Chen H; Zhang X; Wu H; Ma M; Wang Z; Gu N; Zhang Y
Int J Nanomedicine; 2019; 14():921-936. PubMed ID: 30787607
[TBL] [Abstract][Full Text] [Related]
4. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
Ahmadzadeh V; Farajnia S; Hosseinpour Feizi MA; Khavarinejad RA
Protein Expr Purif; 2014 Oct; 102():45-51. PubMed ID: 25088934
[TBL] [Abstract][Full Text] [Related]
5. Controlled release of Rituximab from gold nanoparticles for phototherapy of malignant cells.
Bisker G; Yeheskely-Hayon D; Minai L; Yelin D
J Control Release; 2012 Sep; 162(2):303-9. PubMed ID: 22759981
[TBL] [Abstract][Full Text] [Related]
6. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Exp Cell Res; 2013 Nov; 319(18):2812-21. PubMed ID: 23896027
[TBL] [Abstract][Full Text] [Related]
7. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
Liu YX; Fan DM; Xiong DS; Xu YF; Shao XF; Xu YS; Peng H; Yang M; Qin L; Zhu ZP; Yang CZ
Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
[TBL] [Abstract][Full Text] [Related]
8. Enzyme catalysis enhanced dark-field imaging as a novel immunohistochemical method.
Fan L; Tian Y; Yin R; Lou D; Zhang X; Wang M; Ma M; Luo S; Li S; Gu N; Zhang Y
Nanoscale; 2016 Apr; 8(16):8553-8. PubMed ID: 26786242
[TBL] [Abstract][Full Text] [Related]
9. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
Pandey U; Kameswaran M; Dev Sarma H; Samuel G
Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
[TBL] [Abstract][Full Text] [Related]
10. Controlled synthesis and biomolecular probe application of gold nanoparticles.
Nguyen DT; Kim DJ; Kim KS
Micron; 2011 Apr; 42(3):207-27. PubMed ID: 20952201
[TBL] [Abstract][Full Text] [Related]
11. Thiol-directed synthesis of highly fluorescent gold clusters and their conversion into stable imaging nanoprobes.
Palmal S; Basiruddin SK; Maity AR; Ray SC; Jana NR
Chemistry; 2013 Jan; 19(3):943-9. PubMed ID: 23169542
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
13. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Self-Assembled Monolayers of Peptide Mimotopes of CD20 Antigen and Their Binding with Rituximab.
Leo N; Shang Y; Yu JJ; Zeng X
Langmuir; 2015 Dec; 31(51):13764-72. PubMed ID: 26609837
[TBL] [Abstract][Full Text] [Related]
15. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
18. Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.
Walsh KJ; Al-Quran SZ; Li Y; Braylan RC; Lynch JW
Clin Lymphoma Myeloma; 2007 Jan; 7(4):319-22. PubMed ID: 17324342
[TBL] [Abstract][Full Text] [Related]
19. Rituximab not affected by statins?
Pharmacogenomics; 2009 Feb; 10(2):259. PubMed ID: 19207027
[No Abstract] [Full Text] [Related]
20. Detecting CD20-rituximab specific interactions on lymphoma cells using atomic force microscopy.
Li M; Liu L; Xi N; Wang Y; Dong Z; Li G; Xiao X; Zhang W
Sci China Life Sci; 2010 Oct; 53(10):1189-95. PubMed ID: 20953941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
